27-Aug-2026
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Globe Newswire (Wed, 12-Aug 4:01 PM ET)
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Globe Newswire (Tue, 4-Aug 4:01 PM ET)
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Mon, 27-Jul 8:00 AM ET)
Globe Newswire (Tue, 14-Jul 6:02 AM ET)
PRNewswire (Tue, 14-Jul 6:00 AM ET)
Globe Newswire (Tue, 14-Jul 6:00 AM ET)
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
Globe Newswire (Wed, 8-Jul 2:00 AM ET)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
Market Chameleon (Thu, 18-Jun 6:35 AM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of August 27, 2026, SPRO stock price declined to $1.21 with 534,188 million shares trading.
SPRO has a beta of 0.86, meaning it tends to be less sensitive to market movements. SPRO has a correlation of 0.03 to the broad based SPY ETF.
SPRO has a market cap of $70.46 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC, BUSM, QQQS.
SPRO has underperformed the market in the last year with a return of -34.6%, while the SPY ETF gained +20.7%. In the last 3 month period, SPRO fell short of the market, returning -57.7%, while SPY returned +3.0%. However, in the most recent 2 weeks SPRO has outperformed the stock market by returning +1.7%, while SPY returned -0.2%.
SPRO support price is $1.18 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.